RxDoctor Payments Data

Esteban Lovato, MD

Internal Medicine · Oakland, CANPI 1376610923

Payments from drug & device makers

$1,591in general payments, 2019–2025

Across 86 payments — averaging $18.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$464
  • Novo Nordisk$345
  • Boehringer Ingelheim$235
  • Johnson & Johnson$222
  • Exact Sciences$63
  • Lilly USA, LLC$53
  • plus $207 from 8 others

What the payments were for

  • Food & beverage$1,58199%
  • Education$101%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,591 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$122,514
Medicare patients
225
Services billed
818

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin101$107,569
JanuviaSitagliptin Phosphate82$73,870
OzempicSemaglutide38$41,430
RybelsusSemaglutide29$32,709
EliquisApixaban77$31,706
TrulicityDulaglutide26$25,822
Humulin R U-500 KwikpenInsulin Regular, Human11$15,347
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$9,247
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog24$8,091
SymbicortBudesonide/Formoterol Fumarate16$3,611
Atorvastatin Calcium417$3,220
Albuterol Sulfate HfaAlbuterol Sulfate88$2,837
Lantus SolostarInsulin Glargine,hum.Rec.Anlog43$2,547
Metformin Hcl365$2,283
Lisinopril258$1,983

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$235$107,569101 claims
Novo NordiskOzempic, Rybelsus$345$74,13967 claims
MerckJanuvia$34$73,87082 claims
PfizerEliquis$16$31,70677 claims
Lilly USA, LLCTrulicity, Olanzapine$53$26,68043 claims
AstraZenecaSymbicort$464$3,61116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Oakland

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →